Agilent Technologies, Inc. (NYSE:A) CFO Didier Hirsch sold 72,545 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $62.38, for a total value of $4,525,357.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Didier Hirsch also recently made the following trade(s):
- On Thursday, June 1st, Didier Hirsch sold 5,710 shares of Agilent Technologies stock. The shares were sold at an average price of $60.60, for a total value of $346,026.00.
Shares of Agilent Technologies, Inc. (NYSE A) opened at 62.77 on Thursday. The firm has a 50 day moving average price of $60.55 and a 200-day moving average price of $56.47. The firm has a market cap of $20.21 billion, a P/E ratio of 32.37 and a beta of 1.30. Agilent Technologies, Inc. has a one year low of $42.92 and a one year high of $63.37.
Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.52 by $0.07. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. Agilent Technologies had a net margin of 14.36% and a return on equity of 16.95%. Agilent Technologies’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.49 EPS. Analysts forecast that Agilent Technologies, Inc. will post $2.32 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Didier Hirsch Sells 72,545 Shares of Agilent Technologies, Inc. (A) Stock” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/08/24/didier-hirsch-sells-72545-shares-of-agilent-technologies-inc-a-stock.html.
A has been the topic of several research analyst reports. Barclays PLC restated a “buy” rating and issued a $67.00 price objective on shares of Agilent Technologies in a research note on Wednesday, July 19th. Deutsche Bank AG restated a “buy” rating and issued a $66.00 price objective on shares of Agilent Technologies in a research note on Thursday, June 22nd. BidaskClub lowered Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. BTIG Research upped their price objective on Agilent Technologies from $57.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, May 24th. Finally, Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 price objective on the stock in a research note on Tuesday, May 16th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $63.18.
A number of hedge funds have recently made changes to their positions in the stock. Balentine LLC increased its stake in shares of Agilent Technologies by 2.9% in the second quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock worth $106,000 after buying an additional 50 shares in the last quarter. Sun Life Financial INC increased its stake in shares of Agilent Technologies by 26,144.4% in the second quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock worth $140,000 after buying an additional 2,353 shares in the last quarter. Trust Co. of Vermont increased its stake in shares of Agilent Technologies by 8.1% in the first quarter. Trust Co. of Vermont now owns 2,743 shares of the medical research company’s stock worth $145,000 after buying an additional 205 shares in the last quarter. Acrospire Investment Management LLC increased its stake in shares of Agilent Technologies by 92.3% in the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock worth $148,000 after buying an additional 1,200 shares in the last quarter. Finally, Parallel Advisors LLC increased its stake in shares of Agilent Technologies by 5.3% in the second quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock worth $157,000 after buying an additional 131 shares in the last quarter.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
